The number of microorganisms resistant to antibiotics is increasing each year. Because of that, new research in the field of discovering new antibacterial agents is much needed. Bacterial DNA gyrase and topoisomerase IV are very promising targets. The enzymes are structurally very similar, so there is a possibility for the development of inhibitors that would work on both enzymes at the same time. It is also very important that DNA gyrase is not found in humans, while it is present in every bacteria, which ensures selective toxicity. DNA gyrase and topoisomerase IV control topological state of DNA during replication and are therefore essential for the survival of microorganisms. DNA gyrase consists of two DNA gyrase A (GyrA) subunits and two DNA gyrase B (GyrB) subunits. Subunit GyrA is responsible for cleavage and reunion of the DNA chain, while the main role of subunit GyrB is ATP hydrolysis and thereby providing energy for the cleavage and reunion of the DNA chain.
In the experimental work we designed and synthesized a series of new potential ATP-competitive DNA gyrase B inhibitors. The synthesized compounds possessed 2-amino-6-carboxy-5-hydroxybenzothiazole scaffold, with attached 3,4-dichloro-5-methylpyrrole ring or 4,5-dibromopyrrole ring. Compounds 14, 19 and 21 were tested on DNA gyrase and topoisomerase IV from Escherichia coli and Staphylococcus aureus. The most promising compound 19, which is an acid derivative, with the 3,4-dichloro-5-methylpyrrole ring and attached hydroxyl group at position 5, was very active against DNA gyrase (IC50 = 3,62 ± 0,87 nM ) from bacteria E. coli. For compound 19 we also determined antibacterial activity on bacterial strains Acinetobacter baumannii, Enterobacter aerogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Pseudomonas aeruginosa, S. aureus, E. coli and on two mutated strains of E. coli. Although the compound strongly inhibited the DNA gyrase from E. coli in the enzyme assays, the antibacterial activity on E. coli was weak. This is probably due to the efflux pumps developed by the wild strain in response to antibiotics. For compounds, that inhibited the growth of bacteria by more than 80%, MIC90 values were also determined. Compound 19 showed very low MIC90 values on E. faecalis, K. pneumonia, wild-type S. aureus strain and methicillin resistant S. aureus.
|